Aurion Biotech completes dosing of all subjects in Phase 1/2 CLARA trial
May 1st 2024The trial is evaluating AURN001, a combination cell therapy product comprised of neltependocel (allogeneic human corneal endothelial cells [CECs]) and Y-27632 for the treatment of corneal edema secondary to corneal endothelial dysfunction.